Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06EQN
|
|||
| Former ID |
DIB014983
|
|||
| Drug Name |
XR-510
|
|||
| Synonyms |
CHEMBL100119; XR-510; SCHEMBL243027; BDBM50032353; N-{3-[5-Ethyl-3-(3-fluoro-2''-isopentyloxycarbonylsulfamoyl-biphenyl-4-ylmethyl)-2-propyl-3H-imidazol-4-yl]-3-oxo-propyl}-N-pyridin-3-yl-butyramide(XR510); isopentyloxy 2-[2-(4-{4-ethyl-5-[3-[3-pyridyl(propyl)carboxamidopropanoyl]-2-propyl-1H-1-imidazolylmethyl}-3-fluorophenyl)phenylsulfonyl]caboxamido
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Terminated | [1] | |
| Company |
Xenova Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C39H48FN5O6S
|
|||
| Canonical SMILES |
CCCC1=NC(=C(N1CC2=C(C=C(C=C2)C3=CC=CC=C3S(=O)(=O)NC(=O)OCCC(C)C)F)C(=O)CCN(C4=CN=CC=C4)C(=O)CCC)CC
|
|||
| InChI |
1S/C39H48FN5O6S/c1-6-12-36-42-33(8-3)38(34(46)19-22-44(37(47)13-7-2)30-14-11-21-41-25-30)45(36)26-29-18-17-28(24-32(29)40)31-15-9-10-16-35(31)52(49,50)43-39(48)51-23-20-27(4)5/h9-11,14-18,21,24-25,27H,6-8,12-13,19-20,22-23,26H2,1-5H3,(H,43,48)
|
|||
| InChIKey |
QBFKQSDMKSSMRE-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensin II receptor type-1 (AGTR1) | Target Info | Modulator | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Vascular smooth muscle contraction | ||||
| Renin-angiotensin system | ||||
| Renin secretion | ||||
| Pathways in cancer | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Angiotensin II-stimulated signaling through G proteins and beta-arrestin | |||
| Pathwhiz Pathway | Angiotensin Metabolism | |||
| Muscle/Heart Contraction | ||||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Arf6 signaling events | ||||
| Angiopoietin receptor Tie2-mediated signaling | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | ACE Inhibitor Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| Allograft Rejection | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004861) | |||
| REF 2 | Pharmacology of XR510, a potent orally active nonpeptide angiotensin II AT1 receptor antagonist with high affinity for the AT2 receptor subtype. J Cardiovasc Pharmacol. 1995 Sep;26(3):354-62. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.